Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Acura Pharmaceuticals to Host First Quarter 2013 Financial Results Conference Call on May 3, 2013


Acura Pharmaceuticals to Host First Quarter 2013 Financial Results Conference Call on May 3, 2013

PALATINE, IL -- (Marketwired) -- 04/22/13 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the company plans to report financial results for the first quarter of 2013 following the close of financial markets on Thursday, May 2, 2013. The company will host a conference call to discuss the results on Friday, May 3, 2013 at 8:30 a.m. ET.

To participate in the live conference call, please dial 888-427-9419 (U.S. and Canada) five to ten minutes prior to the start of the call. The participant passcode is 1259095.

A replay of the call will be available beginning May 6, 2013 at 11:30 a.m. ET and ending on May, 27, 2013 on the company's website, and by dialing 888-203-1112 (U.S. and Canada). The replay participant code is 1259095.

About Acura Pharmaceuticals Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary AVERSION(R) and IMPEDE(TM) technologies. In June 2011, the U.S. Food and Drug Administration approved OXECTA(R) which incorporates the AVERSION(R) technology. The Company has a development pipeline of additional AVERSION(R) technology products including other opioids and its IMPEDE(TM) technology for pseudoephedrine hydrochloride products.

The trademark OXECTA(R) is owned by Pfizer Inc.

Contact: for Acura Investor Relations investors@acurapharm.com 847-705-7709

for Acura Media Relations pr@acurapharm.com 847-705-7709

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement